A Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC).
Description: Continuously from date of randomization until date of death from any cause or until patient is registered as off study, whichever came first.Measure: Overall Survival (OS) Time: Monthly after patient is registered off study up to 36 months or until date of death from any cause, whichever came first.
There is one SNP
- Subjects with peripheral neuropathy ≥ grade 2. - Subjects with a known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21. (Subjects with wild type epidermal growth factor receptor (EGFR), unknown status or other type of epidermal growth factor receptor (EGFR) mutation will be considered eligible). --- L858R ---